HHS Outlines Proposal to Tighten DTC Drug Ad Rules
President Donald Trump called on HHS to “ensure transparency and accuracy” in DTC drug advertising last fall.
A proposed rule change from the U.S. Department of Health and Human Services appears to represent the next step in the federal government’s September 2025 vow to rein in direct-to-consumer prescription drug advertising.
The proposal was included in HHS’ regulatory agenda for the rest of 2026, released earlier this month. It constitutes a notice of the department’s plan to publish a formal rule proposal by December, after which the rule would be subject to a discussion period of several months before it could be enacted.
Echoing previous missives from HHS, the proposal claims not to establish “a ban or unreasonable imposition on DTC drug advertising.” Instead, it seeks to close a “loophole” dating back to 1997 by which advertisers are required to share only the most important drug safety information in a pharmaceutical ad, with the rest available through a separate website, phone number or print insert.
That said, supporters and opponents alike of such a rule have long noted that rolling back the “adequate provision” requirement would effectively make broadcast drug ads infeasible due to the amount of time required to spell out the entirety of a medication’s safety information.
The proposal acknowledges that, if enacted, the rule would result in certain “regulatory costs,” as drugmakers may have to purchase additional advertising time or reallocate their existing media buys, or otherwise face “the opportunity cost of choosing not to advertise.”
Despite those “economically significant” potential costs, the proposal claims that eliminating the practice of adequate provision is the only way to carry out last fall’s executive memo, in which President Donald Trump called on HHS to “ensure transparency and accuracy in direct-to-consumer prescription drug advertising, including by increasing the amount of information regarding any risks associated with the use of any such prescription drug required to be provided in prescription drug advertisements.”
Immediately after the memo’s Sept. 9 release, HHS announced it was kicking off a “crackdown on deceptive drug advertising,” which has since comprised the distribution of thousands of untitled and warning letters to drugmakers over their promotional materials.
solli’s Final Thoughts
It’s not yet time to panic over the end of broadcast drug ads as we know them. For one, should the HHS move forward with its proposed rule, it wouldn’t be enacted before the better part of a year. For another, any proposal is sure to face challenges both on a legal basis, citing First Amendment protections of commercial speech, and on a corporate basis, with powerful Big Pharma companies putting pressure on government allies to protect their promotional practices.
Still, for pharma media, there’s certainly no harm in making preparations for potential limits on TV and radio advertising by diversifying marketing strategies, deepening investment in new channels and testing out unbranded HCP and patient engagement tactics.
It’s a win-win either way: Brands and agencies with a more diverse media mix will be not only better prepared for and adaptable to any new DTC regulations but also better positioned to meet audiences where they are, as patients and HCPs increasingly spend less time with traditional channels in favor of newer, digital ones.
